Androgen Receptor Coregulators in Prostate Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The transcriptional activity of androgen receptor (AR) is modulated by coregulators that have a significant influence on a number of functional properties of AR, including the ligand specificity as well as the DNA binding capacity. Because androgens and AR have pivotal roles in the development and growth of normal prostate as well as prostate cancer progression, these coregulators may significantly modulate the events of cancer development and progression. An aberrant regulation or expression of AR coregulators may contribute to androgen and AR-related diseases including prostate cancer. A precise understanding of the roles and mechanisms of individual coregulators may provide valuable information in designing rational therapy against prostate cancer. In this review, we analyzed the up-dated information regarding AR coregulators and their potential roles in prostate cancer progression.Androgens play essential roles in male sexual differentiation, sexual maturation, and the maintenance of spermatogenesis (1, 2). In addition to such vital roles in reproductive organ development, androgens also mediate physiological responses in a wide range of other tissues and organs including the skin, skeletal muscle, cardiac muscle, liver, kidney, central nervous system, and the hematopoietic system (3).The prostate gland is one of the main target organs for androgens, which mediate their biological responses through the AR, a Mr 110,000 ligand-inducible transcription factor that regulates tissue-specific expression of target genes. The AR belongs to the nuclear receptor (NR) superfamily, which also includes estrogen receptor, glucocorticoid receptor, progesterone receptor, vitamin D receptor, thyroid receptor, and retinoic acid receptor (4). It is ubiquitously expressed in human organs with the exception of the spleen and bone marrow, which show complete absence of AR expression. The AR gene is composed of eight exons encoding four functional domains similar to other members of the NR superfamily: a conserved DNA-binding domain, a hinge region, a COOH-terminal ligand-binding domain (LBD), and the less conserved NH2-terminal domain [A/B domain (5)]. Mutational and deletion analyses revealed two transcriptional activation functions including an NH2-terminal activation function (AF-1) involved in ligand-independent activation of AR and a ligand-dependent AF-2 function in the LBD. The AF-2 seems to be involved in more general transcriptional activity because mutation or deletion of the AF-2 domain dramatically reduces the transcriptional activation of AR (6, 7).Since cloning of its cDNA structure in 1988 (8), the AR has been extensively studied to elucidate its biological role in the development and progression of prostate cancer. The growth, differentiation, and maintenance of prostate tissue are dependent on AR and androgens, particularly testosterone and dihydrotestosterone (DHT). Overactivation of the AR signaling pathway may link to the progression of prostate cancer, which remains the most frequently diagnosed malignancy in aging men. Androgens and the AR play key roles in this malignancy, and each year about 30,000 men lose their lives to this malignancy in the United States (9). In 1941, Huggins and Hodges (10) first reported that the normal prostate and early stages of prostate cancer were highly dependent on androgens. Since then, androgen ablation, either by surgical castration or by pharmaco-logical/chemical castration, such as treatment with luteinizing hormone-releasing hormone analogs, has been the cornerstone of treatment in patients with locally advanced or metastatic prostate cancer. Androgen deprivation or the blockade of androgens at the level of the AR usually results in a favorable clinical response and a dramatic tumor regression (11, 12). Although complete disappearance of symptoms is achieved initially, in most cases the response does not imply cure. Upon continued treatment, the therapy fails, and most of the patients develop androgen-independent spread of the disease despite androgen ablation. At present there is no effective therapy for such an androgen-independent prostate cancer. One reason for failure of this androgen ablation therapy may be because of the presence of residual adrenal androgens in the circulation. Castration only abolishes testicular androgens, but the circulating adrenal androgens are readily available and can be converted to testosterone or DHT, the more active form of testosterone, in the prostate. To overcome this effect, antiandrogens are given in combination with castration (the so-called maximal androgen blockade therapy) to block the effects of androgens derived from the adrenals. However, support for additional benefit from this combined therapy is controversial, and a recent 5-year survival study failed to offer much hope for prostate cancer patients (13). Even after complete blockade of androgen action, the response to therapy is lost, tumors continue to grow, and th
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The AR LBD, which is responsible for androgen binding and dimerization, may undergo somatic mutations during prostate cancer progression into the hormone-refractory state (14, 15).”
Backgroundpl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230
Biological Actions of Androgens
MOORADIAN, A. D., MORLEY, J. E., & KORENMAN, S. G. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-1-1 · Cited by 1,080 · cited 1×
“In addition to such vital roles in reproductive organ development, androgens also mediate physiological responses in a wide range of other tissues and organs including the skin, skeletal muscle, cardiac muscle, liver, kidney, central nervous system, and the hematopoietic system (3).”
BackgroundAndrogen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943 · cited 1×
“found to be modulated by a large number of coregulators (42).”
BackgroundSelf-citationTranscriptional activation and nuclear targeting signals of the human androgen receptor.
Simental, J. A., Sar, M., Lane, M. V., French, F. S., & Wilson, E. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52466-2 · Cited by 631
Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., & Akhurst, R. J. (1996) · Cell · doi:10.1016/s0092-8674(00)80127-0 · Cited by 628
Activation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429
Linking β-Catenin to Androgen-signaling Pathway
Yang, F., Li, X., Sharma, M., Sasaki, C. Y., Longo, D. L., Lim, B., & Sun, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111962200 · Cited by 342
Research works printed but not linked: 116
- Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci, 1: d59-71, 1996. · DOI · Paper page
- McLachlan RI, Wreford NG, O’Donnell L, de Kretser DM, Robertson DM. The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. J Endocrinol, 148: 1-9, 1996. · DOI · Paper page
- Tsai M-J, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem, 63: 451-86, 1994. · DOI · Paper page
- MacLean HE, Warne GL, Zajac JD. Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol, 62: 233-42, 1997. · DOI · Paper page
- Durand B, Saunders M, Gaudon C, et al Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J, 13: 5370-82, 1994. · DOI · Paper page
- Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (Wash. DC), 240: 324-6, 1988. · DOI · Paper page
- Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin, 52: 23-47, 2002. · DOI · Paper page
- Greyhack J, Keeler T, Kozlowski J. Carcinoma of the prostate: hormonal therapy. Cancer (Phila.), 60: 589-601, 1987. · DOI
- Prostate Cancer Trialist’s Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet, 355: 1491-8, 2000. · DOI · Paper page
- Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (Bethesda), 93: 1687-97, 2001. · DOI · Paper page
- Koivisto P, Visakorpi T, Rantala I, Isola J. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol, 183: 51-6, 1997. · doi:10.1002/(sici)1096-9896(199709)183:1<51::aid-path1092>3.0.co;2-n
- Palmberg C, Koivisto P, Hyytinen E, et al Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol, 31: 216-9, 1997. · DOI
- Ishioka T, Tanatani A, Nagasawa K, Hashimoto Y. Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor. Bioorg Med Chem Lett, 13: 2655-8, 2003. · DOI
- Steketee K, Timmerman L, Ziel-van der Made AC, et al Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer, 100: 309-17, 2002. · DOI · Paper page
- Krishnan AV, Zhao XY, Swami S, et al A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology, 143: 1889-900, 2002. · doi:10.1210/endo.143.5.8778
- Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate, 42: 239-42, 2000. · DOI · Paper page
- Craft N, Shostak Y, Carey M, Sawyears C. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER2/ neu tyrosine kinase. Nat Med, 5: 280-5, 1999. · DOI · Paper page
- Yeh S, Lin H-K, Kang H-Y, et al From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cells. Proc Natl Acad Sci USA, 96: 5458-63, 1998. · DOI · Paper page
- Blok LJ, de Ruiter PE, Brinkmann AO. Androgen receptor phosphorylation. Endocr Res, 22: 197-219, 1996. · DOI · Paper page
- Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology, 135: 1359-66, 1994. · doi:10.1210/endo.135.4.7925097 · Paper page
- Katzenellenbogen JA, O’Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol, 10: 119-31, 1996. · DOI · Paper page
- Mckenna NJ, Xu J, Nawaz J, et al Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol, 69: 3-12, 1999. · DOI · Paper page
- Onate SA, Tsai SY, Tsai MJ, O’Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (Wash. DC), 270: 1354-7, 1995. · DOI · Paper page
- Voegel JJ, Heine M-J, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J, 15: 3667-75, 1996. · DOI · Paper page
- Le Douarin B, Zechel C, Gamier J-M, et al The N-terminal part of TIF-1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein. EMBO J, 14: 2020-33, 1995. · DOI · Paper page
- Cavailles V, Dauvois S, L’Horset F, et al Nuclear factor RIP 140 modulates transcriptional activation by the estrogen receptor. EMBO J, 14: 3741-51, 1995. · DOI · Paper page
- Puigserver P, Wu Z, Park CW, et al A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 92: 829-39, 1998. · DOI · Paper page
- Moilanen AM, Poukka H, Karvonen U, et al Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol, 18: 5128-39, 1998. · DOI · Paper page
- Spencer TE, Jenster G, Burcin MM, et al Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (Lond.), 389: 194-8, 1997. · DOI · Paper page
- Fu M, Wang C, Reutens AT, et al p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem, 275: 20853-60, 2000. · DOI · Paper page
- Fu M, Wang C, Wang J, et al Androgen receptor acetylation governs transactivation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol, 22: 3373-88, 2002. · DOI · Paper page
- Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem, 277: 25904-13, 2002. · DOI · Paper page
- Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA, 93: 5517-21, 1996. · DOI · Paper page
- Kang H-Y, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem, 274: 8570-6, 1999. · DOI · Paper page
- Fujimoto N, Yeh S, Kang H-Y, et al Isolation and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem, 274: 8316-21, 1999. · DOI · Paper page
- Poukka H, Karvonen U, Yoshikawa N, et al The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci, 113: 2991-3001, 2000. · DOI · Paper page
- Alen P, Claessens F, Schoenmakers E, et al Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1α with multiple steroid receptors and identification of an internally deleted ELE1β isoform. Mol Endocrinol, 13: 117-28, 1999. · DOI · Paper page
- Gao T, Brantley K, Bolu E, McPhaul MJ. RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol Endocrinol, 13: 1645-56, 1999. · doi:10.1210/mend.13.10.0352 · Paper page
- Heinlein CA, Ting H-J, Yeh S, Chang C. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ. J Biol Chem, 274: 16147-52, 1999. · DOI · Paper page
- Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. Δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA, 95: 11083-8, 1998. · DOI · Paper page
- Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA, 95: 7379-84, 1998. · DOI · Paper page
- Miyamoto H, Chang C. Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol, 7: 32-4, 2000. · DOI
- Zhou ZX, He B, Hall SH, Wilson EM, French FS. Domain interactions between coregulator ARA(70) and the androgen receptor (AR). Mol Endocrinol, 16: 287-300, 2002. · doi:10.1210/mend.16.2.0765 · Paper page
- Agoulnik I, Stenoien D, Mancini MA, Weigel N. Keystone Symposium, 2000, Nuclear Receptor Superfamily, Steamboat Springs, CO [abstract]. 302, 116.
- Agoulnik IU, Krause WC, Bingman WE, III, et al Repressors of androgen and progesterone receptor action. J Biol Chem, 278: 31136-48, 2003. · DOI · Paper page
- Han G, Foster BA, Mistry S, et al Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem, 276: 11204-13, 2001. · DOI · Paper page
- Rahman MM, Miyamoto H, Takatera H, et al Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem, 278: 19619-26, 2003. · DOI
- Taplin ME, Bubley GJ, Shuster TD, et al Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med, 332: 1393-8, 1995. · DOI · Paper page
- Culig Z, Hobisch A, Cronauer MV, et al Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol, 7: 1541-50, 1993. · DOI · Paper page
- Shibanuma M, Mashimo J, Kuroki T, Nose K. Characterization of the TGF β1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem, 269: 26767-74, 1994. · DOI · Paper page
- Nishiya N, Sabe H, Nose K, Shibanuma M. The LIM domains of hic-5 protein recognize specific DNA fragments in a zinc-dependent manner in vitro. Nucleic Acids Res, 26: 4267-73, 1998. · DOI
- Yang L, Guerrero J, Hong H, DeFranco DB, Stallcup MR. Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol Biol Cell, 11: 2007-18, 2000. · DOI · Paper page
- Wadman IA, Osada H, Grutz GG, et al The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J, 16: 3145-57, 1997. · DOI · Paper page
- Bach I, Carriere C, Ostendorff HP, Andersen B, Rosenfeld MG. A family of LIM domain-associated cofactors confer transcriptional synergism between LIM and Otx homeodomain proteins. Genes Dev, 11: 1370-80, 1997. · DOI · Paper page
- Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology, 58: 289-94, 2001. · DOI
- Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA, 100: 5124-9, 2003. · DOI
- Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem, 91: 3-12, 2004. · DOI · Paper page
- Thomas SM, Hagel M, Turner CE. Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin. J Cell Sci, 112: 181-90, 1999. · DOI · Paper page
- Matsuya M, Sasaki H, Aoto H, et al Cell adhesion kinase β forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. J Biol Chem, 273: 1003-14, 1998. · DOI
- Wang X, Yang Y, Guo X, et al Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem, 277: 15426-31, 2002. · DOI · Paper page
- Stanzione R, Picascia A, Chieffi P, et al Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Investig, 81: 51-9, 2001. · DOI
- Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal, 12: 123-33, 2000. · DOI · Paper page
- Miyamoto H, Rahman M, Takatera H, et al A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem, 277: 4609-17, 2002. · DOI
- Ito K, Adachi S, Iwakami R, et al N-terminally extended human ubiquitin-conjugating enzymes (E2s) mediate the ubiquitination of RING-finger proteins, ARA54 and RNF8. Eur J Biochem, 268: 2725-32, 2001. · DOI · Paper page
- Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem, 67: 425-79, 1998. · DOI · Paper page
- Hsiao P-W, Chang C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem, 274: 22373-9, 1999. · DOI · Paper page
- Garcia JA, Ou SH, Wu F, et al Cloning and chromosomal mapping of a human immunodeficiency virus 1 “TATA” element modulatory factor. Proc Natl Acad Sci USA, 89: 9372-6, 1992. · DOI
- Wang X, Yeh S, Wu G, et al Identification and characterization of a novel androgen receptor coregulator ARA267-α in prostate cancer cells. J Biol Chem, 276: 40417-23, 2001. · DOI · Paper page
- Jenuwein T, Laible G, Dorn R, Reuter G. SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cell Mol Life Sci, 54: 80-93, 1998. · DOI · Paper page
- Firestein R, Cui X, Huie P, Cleary ML. Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3–9. Mol Cell Biol, 20: 4900-9, 2000. · DOI · Paper page
- Cardoso C, Timsit S, Villard L, et al Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. Hum Mol Genet, 7: 679-84, 1998. · DOI · Paper page
- Cui X, De Vivo I, Slany R, et al Association of SET domain and myotubularin-related proteins modulates growth control. Nat Genet, 19: 331-7, 1998. · DOI · Paper page
- Huang N, vom Baur E, Garnier JM, et al Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J, 17: 3398-412, 1998. · DOI · Paper page
- Hsiao P-W, Lin D-L, Nakao R, Chang C. The linkage of Kennedy’s disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem, 274: 20229-34, 1999. · DOI · Paper page
- Gorlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol, 15: 607-60, 1999. · DOI · Paper page
- Li P, Yu X, Ge K, et al Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol, 161: 1467-74, 2002. · DOI
- Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol, 11: 103-8, 1999. · DOI · Paper page
- Stossel TP, Chaponnier C, Ezzell RM, et al Nonmuscle actin-binding proteins. Annu Rev Cell Biol, 1: 353-402, 1985. · DOI · Paper page
- Fujita H, Allen PG, Janmey PA, et al Induction of apoptosis by gelsolin truncates. Ann N Y Acad Sci, 886: 217-20, 1999. · doi:10.1111/j.1749-6632.1999.tb09420.x
- Koya RC, Fujita H, Shimizu S, et al Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem, 275: 15343-9, 2000. · DOI · Paper page
- Dhanasekaran SM, Barrette TR, Ghosh D, et al Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-6, 2001. · DOI · Paper page
- Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate, 40: 14-9, 1999. · doi:10.1002/(sici)1097-0045(19990615)40:1<14::aid-pros2>3.0.co;2-6
- Pope RK, Pestonjamasp KN, Smith KP, et al Cloning, characterization, and chromosomal localization of human supervillin (SVIL). Genomics, 52: 342-51, 1998. · doi:10.1006/geno.1998.5466
- Ting H-J, Yeh S, Nishimura K, Chang C. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci USA, 99: 661-6, 2002. · DOI · Paper page
- Pestonjamasp KN, Pope RK, Wulfkuhle JD, Luna EJ. Supervillin (p205): a novel membrane-associated, F-actin-binding protein in the villin/gelsolin superfamily. J Cell Biol, 139: 1255-69, 1997. · DOI
- Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem, 277: 17933-43, 2002. · DOI · Paper page
- Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene, 21: 2679-94, 2002. · DOI · Paper page
- Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of β-catenin mutations in prostate cancer. Prostate, 45: 323-34, 2000. · DOI · Paper page
- Damalas A, Kahan S, Shtutman M, Ben-Ze’ev A, Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J, 20: 4912-22, 2001. · DOI · Paper page
- Muscat GE, Burke LJ, Downes M. The corepressor N-CoR and its variants RIP13a and RIP13Delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. Nucleic Acids Res, 26: 2899-907, 1998. · DOI · Paper page
- Heinzel T, Lavinsky RM, Mullen TM, et al A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (Lond.), 387: 43-8, 1997. · DOI · Paper page
- Alland L, Muhle R, Hou H, Jr, et al Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (Lond.), 387: 49-55, 1997. · DOI · Paper page
- Liao G, Chen LY, Zhang A, et al Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem, 278: 5052-61, 2003. · DOI · Paper page
- Reutens AT, Fu M, Wang C, et al Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol, 49: 797-811, 2001. · doi:10.1210/mend.15.5.0641 · Paper page
- Dedhar S, Rennie PS, Shago M, et al Inhibition of nuclear hormone receptor activity by calreticulin. Nature (Lond.), 367: 480-3, 1994. · DOI · Paper page
- Sharma M, Zarnegar M, Li X, Lim B, Sun Z. Androgen receptor interacts with a novel MYST protein, HBO1. J Biol Chem, 275: 35200-8, 2000. · DOI · Paper page
- Kang H-Y, Lin H-K, Hu Y-C, et al From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA, 98: 3018-23, 2001. · DOI · Paper page
- Chipuk JE, Cornelius SC, Pultz NJ, et al The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J Biol Chem, 277: 1240-8, 2002. · DOI · Paper page
- Kang H-Y, Huang K-E, Chang S-Y, et al Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem, 277: 43749-56, 2002. · DOI · Paper page
- Massague J. Transforming growth factor-α. A model for membrane-anchored growth factors. J Biol Chem, 265: 21393-6, 1990. · DOI · Paper page
- Attisano L, Wrana JL, Lopez-Casillas F, Massague J. TGF-β receptors and actions. Biochim Biophys Acta, 122: 71-80, 1994. · DOI · Paper page
- Lamm ML, Sintich SM, Lee C. A proliferative effect of transforming growth factor-β1 on a human prostate cancer cell line, TSU-Pr1. Endocrinology, 139: 787-90, 1998. · DOI
- Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-β1 in prostate cancer. Microsc Res Tech, 52: 411-9, 2001. · DOI
- Guo Y, Kyprianou N. Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res, 59: 1366-71, 1999. · DOI
- Barrack ER. TGF β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate, 31: 61-70, 1997. · DOI · Paper page
- Derynck R, Jarrett JA, Chen EY, et al Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature (Lond.), 316: 701-5, 1985. · DOI · Paper page
- Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med, 1: 282-4, 1995. · DOI · Paper page
- Adler HL, McCurdy MA, Kattan MW, et al Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol, 161: 182-7, 1999. · DOI · Paper page
- Chang C, Da Silva SL, Ideta R, et al Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily. Proc Natl Acad Sci USA, 91: 6040-4, 1994. · DOI
- Lee Y-F, Young W-J, Burbach JP, Chang C. Negative feedback control of the retinoid-retinoic acid/retinoid X receptor pathway by the human TR4 orphan receptor, a member of the steroid receptor superfamily. J Biol Chem, 273: 13437-43, 1998. · DOI
- Lee Y-F, Pan H-J, Burbach JP, Morkin E, Chang C. Identification of direct repeat 4 as a positive regulatory element for the human TR4 orphan receptor. A modulator for the thyroid hormone target genes. J Biol Chem, 272: 12215-20, 1997. · DOI
- Lee Y-F, Young W-J, Lin W-J, Shyr C-R, Chang C. Differential regulation of direct repeat 3 vitamin D3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor. J Biol Chem, 274: 16198-205, 1999. · doi:10.1074/jbc.274.23.16198
- Young W-J, Smith SM, Chang C. Induction of the intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFRα) gene by the TR4 orphan receptor. A member of steroid receptor superfamily. J Biol Chem, 272: 3109-16, 1997. · DOI
- Lee Y-F, Shyr C-R, Thin TH, Lin W-J, Chang C. Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamily. Proc Natl Acad Sci USA, 96: 14724-9, 1999. · DOI · Paper page
- Zhang Y, Yang Y, Yeh S, Chang C. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol, 24: 1044-57, 2004. · DOI
- Zheng P, Eastman J, Vande Pol S, Pimplikar SW. PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein. Proc Natl Acad Sci USA, 95: 14745-50, 1998. · DOI · Paper page
Cited by
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377
Molecular cell biology of androgen receptor signalling
Bennett, N. C., Gardiner, R. A., Hooper, J. D., Johnson, D. W., & Gobe, G. C. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.013 · Cited by 292
Direct, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element
Magee, J. A., Chang, L.-W., Stormo, G. D., & Milbrandt, J. (2006) · Endocrinology · doi:10.1210/en.2005-1001 · Cited by 174
Lin, J., Xu, J., Tian, H., Gao, X., Chen, Q., Gu, Q., Xu, G., Song, J., & Zhao, F. (2007) · International Journal of Cancer · doi:10.1002/ijc.23016 · Cited by 125
Metadata
- Authors
- Rahman, M., Miyamoto, H., & Chang, C.
- Venue
- Clinical Cancer Research
- Published
- 2004-04-01
- Volume
- 10
- Issue
- 7
- Pages
- 2208-2219
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2096870409
- Cited by
- 102
- References
- 14
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen Receptor Coregulators in Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-0746-3
- The paper
- Rahman, M., Miyamoto, H., & Chang, C. (2004). Androgen Receptor Coregulators in Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-0746-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.